[ad_1]
Only 0.2 percent of the population that has been vaccinated in Chile in the first days of the campaign has had expected side effects presumably attributable to the Pfizer / BioNTech formula, according to a balance of the Institute of Public Health.
Until today 8,638 health workers, the first priority group, were immunized in the Metropolitan, Biobío, La Araucanía and Magallanes regions: of them, only in 21 is there a suspected adverse reaction.
The most frequent symptoms reported -and expected- have been headache, fatigue, pain at the injection site, itching and rash, “reactions considered you wouldn’t be“, specified the ISP, through the Subdepartment of Pharmacovigilance.
Two of the cases were classified as “serious”, but not serious, because they required hospitalization.
People with side effects -20 from the Metropolitana and one from Biobío- “are being monitored and the follow-up of cases, to be evaluated and thus be able to confirm or rule out the relationship with inoculation“.
The ISP director (s), Heriberto Garcia, stated that “we will continue to pay attention to the reports that health professionals send us from healthcare centers, with the aim of evaluating the safety of the vaccine and monitoring the inoculation process with the Pfizer vaccine and the next vaccines that arrive. to the country”.
“It is important that all health professionals notify, since when vaccination is massive we have to have the reports online, to quickly manage the information we receive in real time,” he said.
The Events Allegedly Attributed to Vaccination or Immunization (Esavi) must be reported directly to the National Center for Pharmacovigilance of the ISP, within the established deadlines (click here); or also to the Pfizer laboratory, which in turn notifies the ISP.
